1 / 9

Mesenchymal Stem Cells - Advances And Applications

Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal cells. To know more : https://www.bharatbook.com/biotechnology-market-research-reports-90794/mesenchymal-stem-cells-advances-and-applications.html

bharatbookseo
Download Presentation

Mesenchymal Stem Cells - Advances And Applications

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Mesenchymal Stem Cells - Advances And Applications

  2. Summary This global strategic report is produced for:• Management of stem cell companies• Management of regenerative therapy companies• Stem cell industry investorsIt is designed to increase your efficiency and effectiveness in:1. Commercializing mesenchymal stem cell (MSC) products, technologies, and therapies2. Making intelligent investment decisions3. Launching high-demand products4. Selling effectively to your client base5. Increasing revenue from MSC products and services6. Taking market share from your competition W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  info@bharatbook.com

  3. Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal cells. MSCs are of intense therapeutic interest because they represent a population of cells with the potential to treat a wide range of acute and degenerative diseases.MSCs are advantageous over other stem cells types for a variety of reasons: they avoid the ethical issues that surround embryonic stem cell research, and repeated studies have found MSCs to be immuno-privileged, which make them an advantageous cell type for allogenic transplantation. MSCs reduce both the risks of rejection and complications of transplantation. Recently, there have been advances in the use of autologousmesenchymal stem cells to regenerate human tissues, including cartilage, meniscus, tendons, bone fractures, and more. W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  info@bharatbook.com

  4. This global strategic report explores recent advances in MSC research applications, research priorities by market segment, and the competitive environment for MSC research products. It also identifies trend and growth patterns within the MSC industry. Because it is important for pharmaceutical companies interested to understand underlying forces affecting the MSC market, this report also presents a range of topics that apply to these companies, including how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies. W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  info@bharatbook.com

  5. Literature and data concerning the biology and differentiation potential of mesenchymal stem cells (MSCs) has expanded rapidly over the past 10 years, with more than 13,000 publications now exploring aspects of MSC biology, behavior, and applications. In particular, MSCs appear to be an exceptionally promising tool for cell therapy because of their unusual characteristics, which partially mimic those of embryonic stem cells, while having advantages in terms of availability, expandability, transplantability, and ethical implications.Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as from their ability to migrate to sites of tissue injury/inflammation or tumor growth. These localization properties present a promising strategy for targeted introduction of therapeutic agents through MSC gene therapy. In addition, MSCs possess strong immunosuppressive properties that medical researchers are exploiting for both autologous as well as heterologous therapies. W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  info@bharatbook.com

  6. Clinical Progress with MSCsAs mentioned, mesenchymal stem cells (MSCs) have inspired a lot of activity over the past ten years as a novel therapeutic model for a wide range of diseases. Presently, MSCs-based clinical trials are being conducted for twelve types of disease conditions, with many completed trials showing their safety and efficacy. The clinical utility of MSCs are mostly attributed to their four key biological properties, which are their potential to: 1. Migrate to sites of inflammation caused by tissue injury when injected intravenously2. To get differentiated into different cell types3. To release different bioactive molecules having the potential of stimulating recovery of injured cells and preventing inflammation4. To accomplish immunomodulatory functions W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  info@bharatbook.com

  7. Currently, there are 128 clinical trials involving MSCs are in progress in different parts of the world, including China, the European Union, the United States, the Middle East, and South Korea. Among these trials, 45 (35%) are exploiting MSCs for various disease indications. Currently, four major clinical trials using MSCs have reached Phase III. Stempeutics Research’s product candidate Stempeucel is being evaluated in two centers for treating critical leg ischemia. Prochymal is the product candidate from Osiris Therapeutics and it is being used for treating graft vs. host disease (GvHD). The company is also testing Prochymal for treating Crohn’s disease in another Phase III trial. The Australian company Mesoblast is testing an ‘off-the-shelf’ mesenchymal precursor product candidate for treating patients with hematological malignancies. W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  info@bharatbook.com

  8. Table of Contents 1. REPORT OVERVIEW 1.1 Statement of the Report 1.2 EXECUTIVE SUMMARY 2. INTRODUCTION 2.1 Regenerative Medicine (RM) and Advanced Therapies Industry: A Brief Overview 2.2 Global Breakdown of Major RM Industries by Region 2.3 Breakdown of Global RM Companies by Type 2.4 Number of Therapeutic Companies, Approved Products and Clinical Trials in RM Sector 2.5 Number of RM Clinical Trials by Phase of Development W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  info@bharatbook.com

  9. To view the full Executive Summary and Table of Contents, please visit: Mesenchymal Stem Cells - Advances And Applications Contact Us:Bharat Book BureauCall us: +91-22-27810772 / 73Email id : info@bharatbook.comBlog : https://www.bharatbook.com/blog/ Follow Us On :

More Related